Suppr超能文献

自然杀伤细胞过继性细胞免疫治疗:利用抗癌第一道防线

Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.

作者信息

Davis Zachary B, Felices Martin, Verneris Michael R, Miller Jeffrey S

机构信息

From the Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN.

出版信息

Cancer J. 2015 Nov-Dec;21(6):486-91. doi: 10.1097/PPO.0000000000000156.

Abstract

Natural killer (NK) cells constitute an important component of the initial immunological response against transformed cells. However, chronic exposure to the tumor microenvironment can fundamentally alter the ability of NK cells to sufficiently control tumor progression. Thus, the adoptive transfer of healthy, functional NK cells as an interventional therapy has been an area of great interest for improving patient outcomes. Recent developments in the field have provided a better understanding of what makes the NK compartment effective against malignant cells. Moreover, there are now multiple potential sources of NK cell products for infusion as well as techniques to manipulate these cells to enhance their antitumor functions. This review explores the advantages and disadvantages of various sources of NK cells as well as prospective therapeutic enhancements to adoptively transferred NK cells.

摘要

自然杀伤(NK)细胞是针对转化细胞的初始免疫反应的重要组成部分。然而,长期暴露于肿瘤微环境会从根本上改变NK细胞充分控制肿瘤进展的能力。因此,作为一种介入治疗手段,过继性输注健康、功能正常的NK细胞一直是改善患者预后的一个备受关注的领域。该领域的最新进展使人们对NK细胞区室有效对抗恶性细胞的机制有了更深入的了解。此外,目前有多种可用于输注的NK细胞产品来源,以及操纵这些细胞以增强其抗肿瘤功能的技术。本综述探讨了各种NK细胞来源的优缺点,以及对过继性转移的NK细胞进行前瞻性治疗增强的方法。

相似文献

1
Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.
Cancer J. 2015 Nov-Dec;21(6):486-91. doi: 10.1097/PPO.0000000000000156.
2
Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Crit Rev Immunol. 2016;36(4):329-347. doi: 10.1615/CritRevImmunol.2017019376.
3
Improving natural killer cell cancer immunotherapy.
Curr Opin Organ Transplant. 2015 Dec;20(6):671-80. doi: 10.1097/MOT.0000000000000243.
4
Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
Trends Mol Med. 2017 Dec;23(12):1156-1175. doi: 10.1016/j.molmed.2017.10.002. Epub 2017 Nov 10.
5
Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.
J Hematother Stem Cell Res. 2001 Aug;10(4):535-44. doi: 10.1089/15258160152509145.
7
Natural killer cells: can they be useful as adoptive immunotherapy for cancer?
Expert Opin Biol Ther. 2005 Feb;5(2):163-72. doi: 10.1517/14712598.5.2.163.
9
NK cell-based cancer immunotherapy: from basic biology to clinical application.
Sci China Life Sci. 2015 Dec;58(12):1233-45. doi: 10.1007/s11427-015-4970-9. Epub 2015 Nov 20.
10
NK cell-based immunotherapy for cancer.
Semin Immunol. 2017 Jun;31:37-54. doi: 10.1016/j.smim.2017.07.009. Epub 2017 Aug 31.

引用本文的文献

1
Tissue-resident immune cells in cervical cancer: emerging roles and therapeutic implications.
Front Immunol. 2025 Apr 22;16:1541950. doi: 10.3389/fimmu.2025.1541950. eCollection 2025.
3
NK cell subsets and dysfunction during viral infection: a new avenue for therapeutics?
Front Immunol. 2023 Oct 19;14:1267774. doi: 10.3389/fimmu.2023.1267774. eCollection 2023.
5
Off-the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia.
Blood Adv. 2023 Oct 24;7(20):6225-6239. doi: 10.1182/bloodadvances.2022007405.
6
DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy.
Front Immunol. 2023 Jun 8;14:1197053. doi: 10.3389/fimmu.2023.1197053. eCollection 2023.
7
Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions.
Front Immunol. 2023 May 25;14:1175118. doi: 10.3389/fimmu.2023.1175118. eCollection 2023.
9
Advances in NK cell therapy for brain tumors.
NPJ Precis Oncol. 2023 Feb 15;7(1):17. doi: 10.1038/s41698-023-00356-1.
10
Emerging frontiers in immuno- and gene therapy for cancer.
Cytotherapy. 2023 Jan;25(1):20-32. doi: 10.1016/j.jcyt.2022.10.002. Epub 2022 Oct 22.

本文引用的文献

1
Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.
Front Immunol. 2015 Jun 10;6:266. doi: 10.3389/fimmu.2015.00266. eCollection 2015.
3
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
Clin Cancer Res. 2015 Sep 15;21(18):4055-61. doi: 10.1158/1078-0432.CCR-15-0304. Epub 2015 May 21.
4
Utilizing chimeric antigen receptors to direct natural killer cell activity.
Front Immunol. 2015 Apr 28;6:195. doi: 10.3389/fimmu.2015.00195. eCollection 2015.
5
Effect of tumor cells and tumor microenvironment on NK-cell function.
Eur J Immunol. 2014 Jun;44(6):1582-92. doi: 10.1002/eji.201344272.
6
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
Blood. 2014 Jun 19;123(25):3855-63. doi: 10.1182/blood-2013-10-532531. Epub 2014 Apr 9.
7
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
Haematologica. 2014 Jun;99(6):e81-3. doi: 10.3324/haematol.2013.103085. Epub 2014 Mar 21.
8
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Blood. 2014 May 8;123(19):3016-26. doi: 10.1182/blood-2013-10-533398. Epub 2014 Mar 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验